Additional Advances in Squamous Non–Small Cell Lung Cancer Research and Clinical Trials With Mark Kris, MD
Keira Smith
Expert Analysis
In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education (CME)/nursing continuing professional development (NCPD) activity. A year later, Dr. Kris sat down again with Oncology Data Advisor to share the progress that has occurred in this field and the important considerations to keep in mind when treating patients with squamous NSCLC in 2023.  
Emphasizing Communication and Expectations for Lung Cancer Side Effects With Blanca Ledezma, MSN, NP
Keira Smith
Expert Analysis
With the advent of targeted therapies in lung cancer, patients are experiencing improved outcomes through personalized medicine. However, education regarding potential toxicity is crucial. In this interview, Blanca Ledezma, MSN, NP, shares the importance of setting up expectations for the side effects of targeted therapies for lung cancer and empha...
Personalizing Lung Cancer Care Through Biomarkers and Precision Medicine With Blanca Ledezma, MSN, NP
Keira Smith
Expert Analysis
In this interview with Oncology Data Advisor, Blanca Ledezma, MSN, NP, elucidates the current landscape of therapeutically actionable biomarkers in lung cancer and the promising future of precision medicine in this field. In addition, she explains the clinical applications for lung cancer biomarkers in nursing practice, including unique toxicity management and patient education for novel therapies.  
World Lung Cancer Day With Beth Sandy, MSN, CRNP, and Corey Langer, MD
Keira Smith
Expert Analysis
On August 1st, Oncology Data Advisor hosted a live panel discussion in honor of World Lung Cancer Day, featuring Beth Sandy, MSN, CRNP, and Corey Langer, MD, both of the University of Pennsylvania Abramson Cancer Center. Ms. Sandy and Dr. Langer discussed the improvements in survival that have occurred in recent years due to the development of novel therapies, groundbreaking developments in the fields of immunotherapy and targeted therapy, and exciting advances that lay on the horizon for patients with lung cancer in the coming years.  
Advancing Treatment for Non–Small Cell Lung Cancer: Exploring the Results of Adagrasib With Alexander Spira, MD, PhD, FACP
Lyn Brook
Expert Analysis
At the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Alexander Spira, MD, PhD, FACP, Director of the Thoracic and Phase I Program at the Virginia Cancer Specialists, the US Oncology Network, met with Oncology Data Advisor to discuss his presentation about adagrasib for KRAS G12–mutated non–small cell lung cancer with active central nervous system (CNS) metastases.  

Copyright © 2022 Oncology Data Advisor. All rights reserved.